- Home
- ICG vs ABOS Comparison
ICG vs ABOS Comparison
Compare ICG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICG | ABOS |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 114.5M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICG | ABOS |
|---|---|---|
| Price | $2.14 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.50 | ★ $7.67 |
| AVG Volume (30 Days) | 90.6K | ★ 212.9K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.43 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $36,367,850.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.98 | N/A |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $0.93 | $0.86 |
| 52 Week High | $4.36 | $2.46 |
Technical Indicators
Market Signals| Indicator | ICG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 53.90 |
| Support Level | $1.80 | $1.76 |
| Resistance Level | $2.07 | $1.99 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 72.64 | 69.15 |
Price Performance
Historical ComparisonAbout ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.